

Subject Index

(CA = Carbonic anhydrase)

- A**etaldehyde hydrate, dehydration by CA, 109-111
- Acetate adduct of cobalt CA, magnetic circular dichroic spectra of, 140
- Acetate inhibitor of CA
for carboxyketoethylated cobalt CA, 124
and carboxylate resonance in cobalt CA, 120
- Acetazolamide
and acetyl CoA carboxylase activity, 523, 526
and acid-base balance in crab, 544-545
affecting histochemical staining of tissues, 372
as anticonvulsant, 10, 490-491
and bicarbonate reabsorption in kidney, 531-535, 538-539, 541-543
binding sites in tissues, 12
and calcification reactions, 457
and calcium uptake by chick chorioallantoic membrane, 467
as carbonic anhydrase inhibitor, 10, 165, 190
comparative studies of, 171, 615-616
for inactive CA I in aldosteronism, 303
in kidney, 200-201
in lens, 583
for muscle CA III, 152, 156-158
in nonmammalian red cells, 173, 174
in plants, 224-226
and carboxyketoethylated cobalt CA, 124
and carboxylate resonance in cobalt CA, 120
and cerebrospinal fluid flow, 12, 607
and ciliary body electrical potential, 580-581
diuretic action of, 610
in physyema, 554
and fatty acid synthesis in liver, 525-526
in glaucoma, 10, 12, 571, 609-610
plasma concentrations affecting, 611
and iodide uptake in thyroid, 604
measurement of activity in cells, 424-425
optimal dosage of, 616-617
and oxyntic cell CA activity, 593
placental transfer of, 450-455
plasma levels of, and physiological effects, 611-613
properties of, 569, 571
as pyruvate carboxylate inhibitor, 522
renal effects of, 11, 12, 531-535, 538-539, 541-543
respiratory effects of, 548
and shell-less egg production, 457
side effects of, 613, 614
sodium loss from, 7
teratogenicity of, 447-450
transcorneal diffusion of, 572
as ubiquitin inhibitor, 246
in ulcer therapy, 572-573, 587-591, 597-600, 610
and gastric microcirculation, 601-603
and urea production in hepatocytes, 519-520
- Acetyl CoA carboxylase, inhibition by acetazolamide, 523, 526
- Acid phosphatase activity, in rabbit CA III, 179
- Acid secretion
CA inhibitors affecting, 572, 587-591, 597, 610
by chorioallantoic membrane of chicks, 460-462, 470
- Acidosis, and ammonia excretion in alligator, 510
- Active sites of CA, 341-345
ligand exchange in, 99-106
mechanisms in, 76-83
in membrane-bound CA, 197
modifications affecting catalytic activity, 114-127
in muscle CA, 179-181, 341-345
nature of, in CA I, 56
nonpolar and polar construction of, 44
transfer of H^+ to reaction medium, 62-63
water structure in CA II, 66
- Adipocyte CA, 264, 393
- Age, and erythrocyte CA levels, 277-278, 280
- Alcohol dehydrogenase
chemical shift of cadmium-113 for, 41, 42
crystal structure of, 27
- Aldehydes, hydration of, 22
- Aldosterone, and activity of CA in rat small intestinal mucosa, 306-308
- Aldosteronism, inactive form of erythrocyte CA I in, 302-304
- Algal CA, 222-236
diversity of, 238-240

- Alkaline phosphatase
cadmium, 37
compared to zinc enzyme, 45-46
chemical shift of cadmium-113 for, 41, 42
crystal structure of, 27
E-P intermediate of, 36, 45, 46
zinc, 36
compared to cadmium enzyme, 45-46
- Alkalosis, and ammonia excretion in alligator, 510
- Alkyl carbonates, interaction with CA, 77-83
- Alligator CA
and ammonia synthesis in kidney, 508-511
and glucose synthesis from lactate, 511-513
inhibitors affecting, 511-513, 522
and metabolic rate, 505-506
in retina, 439
- Altitude sickness, CA inhibitors in, 555, 556, 610
- Aluminum, and cerebrospinal fluid formation, 607
- Amacrine neuron CA in retina
in amphibians, 441
in chicken, 434
in mouse, 435, 438
- Amiloride, and sodium-hydrogen exchange in glial cells, 491
- Amino acids
sequence analysis of carbonic anhydrases, 174. *See also* Structure of carbonic anhydrases
synthesis of, and CA activity, 506-508
- 2-Amino-1,3,4-thiadiazole-5-sulfonamide, and ciliary body electrical potential, 580-581
- Ammonia synthesis in alligator kidney, CA role in, 508-511
- Amphibian CA
in red cells, 172
in retina, 441
- Androgens, and activity of CA III in rat liver, 287-300
- Anion inhibition of CA, 165, 167
comparative studies of, 171-172, 176
and inhibited forms of CA, 101
ligand exchanges in, 103
for muscle CA III, 134-135
for nonmammalian CA, 173, 174
- Appendiceal CA, 263, 364, 394
- Aqueous humor CA, 580-581
- Arginine residues in muscle CA III, 156, 160, 179, 180
- Arsenate, inhibiting phosphatase activity of CA III, 156
- Arthropod CA, 544
- Aspartate transcarbamylase, crystal structure of, 27
- Astrocyte CA, 366, 481, 494, 495, 499, 502
- Atropine, and oxyntic cell CA activity, 593
- Avian CA
in muscle, 175
in red cells, 172
- Axonal CA, 408
- Azide inhibition of CA
for carboxyketoethylated cobalt CA, 124
and carboxylate resonance in cobalt CA, 119
for muscle CA III, 131-132, 134-135
in plants, 225-226
- B**arnacle calcification, and CA activity, 457
- Benzoate adduct of cobalt CA, magnetic circular dichroic spectra of, 140
- Benzolamide
physiologic effects of, 556
properties of, 569, 570
renal effects of, 15, 200
- Bicarbonate
adduct of cobalt CA, magnetic circular dichroic spectra of, 140
binding to cobalt, 93, 95
dehydration of, 1, 31
inhibition by alkyl carbonates, 79-83
isotope effects for, 77
in muscle CA III, 179, 189, 181
pH affecting, 76
proton transfer in, 85
export in cells with cytosolic CA, 388-389
and fatty acid synthesis, 523
and gluconeogenesis, 522
and hepatocyte metabolism, 518-523
inhibiting carbon dioxide hydration, 80
interaction with CA, 77-79
interconversion with carbon dioxide, 63-65
in absence or inhibition of CA, 585
comparative studies of, 174
and isozyme III kinetics, 129, 133
"ping-ping-pong" path in, 104-106
reactions in, 99-106
intracellular loss after CA inhibition, 507-508, 509
NMR relaxation times in cobalt CA, 143-144
and photosynthesis in underwater plants, 233
rate of formation in organs, 574
renal reabsorption of, CA affecting, 200-201

- role in brain, 492
- in saliva, from ovine parotid gland, 212
- transport in kidney, 528-535
- acetazolamide affecting, 531-535, 538-539, 541-543
- and urea metabolism, 518-522
- Biliary duct CA, cytosolic, 388
- Black Americans, erythrocyte CA in, 277-278
- Bone CA, 263
- deficiency of, 268
- Bovine CA
 - active-site mechanisms of, 76-83
 - carboxyketoethylated, 123-127
 - cobalt-substituted, 89-97
 - dehydration of acetaldehyde hydrate, 109-111
 - denaturation and renaturation of, 137-139
 - dynamic NMR studies of, 146-148
 - inhibition by neoprontosil, 175
 - isozyme I, 165
 - isozyme III, 168, 179-180
 - amino acid composition of, 154
 - liquid chromatography of, 140-142
 - magnetic circular dichroic spectra of ligand adducts, 140
 - in ox. *See* Ox CA
 - polymorphisms of, 186
 - positron lifetime studies of conformational dynamics, 149-151
 - pulmonary, 551
 - structure of, 187
- Brain CA, 165, 263, 481-492
 - and activity of 2'3' cyclic nucleotide 3' phosphohydrolase, 498-500
 - in astrocytes, 366, 481, 494, 495, 499, 502
 - in audiogenic seizure mice, 502-504
 - as bicarbonate source, 492
 - biogenesis of, 484-490
 - cerebellar, 361-362, 498
 - cerebral, 361-362, 498-500
 - cytosolic, 388
 - deficiency of, 268-269
 - human, 361-362, 364, 366
 - membrane-bound, 198, 199, 268, 481, 482
 - in myelin, 393, 494-496. *See also* Myelin CA
 - in oligodendrocytes, 361-362, 366, 393, 492, 494-496, 498-500, 502
 - purification of, 482-483
 - in quaking mice, 481, 482
 - receptors for, 486-489
 - retinal. *See* Retinal CA
 - in seizure activity, 490-492
 - side effects from inhibitors of, 614
 - two-dimensional gel electrophoresis of, 483-484
- Bromide adduct of cobalt CA, magnetic circular dichroic spectra of, 140
- Bromoacetate, in modification of histidine, 115, 116-122
- Bromopyruvate, in modification of histidine, 115, 123-127
- Bronchial CA. *See* Tracheobronchial CA
- Buffer concentration, and hydration turnover numbers for CO₂, 62
- Butanedione, and bicarbonate dehydration in muscle CA III, 179, 180, 181
- C**
 - Cadmium alkaline phosphatase, 37
 - compared to zinc enzyme, 45-46
 - Cadmium carbonic anhydrase, 35-36
 - Cadmium isotopes, as probes of metalloenzyme active sites, 41-47
 - Calcification, and CA activity, 457-458
 - Calcitonin, and CA activity in osteoclasts, 474
 - Calcium transport, in chick chorioallantoic membrane, 459-470, 479
 - Calmodulin, chemical shift of cadmium-113 for, 41, 42
 - Capillary CA, 199, 201, 253, 377-379, 399
 - and carbon dioxide exchange, 561-563
 - gastric, inhibitors affecting, 601-603
 - in kidneys, 377, 379, 562-563
 - membrane-bound, 201
 - pulmonary, 379, 551
 - kinetics and activity of, 565-567
 - Carbachol, and CA activity in gastric mucosa, 475
 - Carbamyl choline, and oxyntic cell CA activity, 592-595
 - Carbamyl phosphate synthetase, in cayman kidney, 511
 - Carbon-13 NMR probes. *See* Nuclear magnetic resonance
 - Carbon dioxide
 - binding to cobalt, 96
 - exchange with bicarbonate, 63-65
 - in alveolar-capillary membrane, 550-551
 - in gills, 553
 - facilitated diffusion of, 576
 - hydration of, 31
 - assays of, 167
 - buffer dependence of, 62
 - buffer-independent, 62, 65
 - by carbonic anhydrase III, 129-135
 - in carboxyketoethylated cobalt enzyme, 124
 - comparative kinetics in vertebrates, 165-176
 - inhibition of, 69-73, 79-83
 - isotope effects for, 65, 67, 77

- and measurement of CA activity in cells, 415-428
mechanisms in, 99-100
pH affecting, 76
proton transfer in, 84-85
and solvent hydrogen isotope effects, 134
steady-state and equilibrium exchange constants in, 133
and turnover numbers for isoenzymes, 61, 62
by ubiquitin, 245-247
zinc-hydroxide mechanisms in, 122
interconversion with bicarbonate in absence or inhibition of CA, 585
comparative studies of, 174
and isozyme III kinetics, 129, 133
"ping-ping-pong" path in, 104-106
reactions in, 99-106
NMR relaxation times in cobalt CA, 143-144
output in muscle during exercise, 552
zinc interaction with, 63
Carbon dioxide hydratase activity in muscle CA, 155, 163
Carbonic acid
dehydration of, 31
relation to carbonic anhydrase, 1
Carbonic anhydrase A, 189
Carbonic anhydrase I (CA B), 20-21, 183, 359
active site of, 341-345
Australia-9 variant of, 252-255, 259
carboxymethylated, at active-site His-200, 115, 116-122
comparative studies of, 165-176
compared to CA II, 184, 186
conserved region of, 351-352
deamidation product of, 189
deficiency of, 265
distribution of, 263-264, 364, 394
hydration turnover number for CO₂, 61
inhibition by imidazole, 21-22
kinetic properties of, 61-73
purification of mRNA from, 324-331
in red cells, 549
refinement process for, 49-59
methods in, 50
structure after, 53-59
in renal tubular acidosis, 192
unique invariant residues for, 339
variants in Australasia, 249-260
Carbonic anhydrase II (CA C), 20-21, 183, 359
active site of, 341-345
water structure in, 66
Australia-4 variant of, 252-253, 255, 257
carboxyketoethylated, at active-site His-64, 115, 123-127
comparative studies of, 165-176
compared to CA I, 184, 186
conserved region of, 351
crystal structure of, 27
deficiency of, 265-271
distribution of, 263-264, 364, 394
gene isolation for, 332-334
genes in mouse and human, 300-320
hydration turnover number for CO₂, 61
Jogjakarta variant of, 255-257, 259
kinetic properties of, 61-73
Melbourne variant of, 255-257, 260
in muscle, 263
in normal and neoplastic cells, 367
in platelets, 207-209
possibility of more than one CA II gene, 269, 318-320
in red cells, 549
unique invariant residues for, 339
variable compartmentalization in retina, 430-445
variants in Australasia, 249-260
Carbonic anhydrase III, 22-23, 183, 309, 359
active site of, 179-181, 341-345
in adipose cells, 264
and carbon dioxide hydration
anion inhibition of, 134-135
and solvent hydrogen isotope effects, 134
steady-state and equilibrium exchange constants in, 133
turnover number for, 61
comparative studies of, 165-176
compared to ubiquitin, 190, 191
conserved region of, 351, 353
distribution of, 263-264
elevated levels with CA II deficiency, 284-285
in erythrocytes, 264, 284
esterase activity of, 154-156, 163
in fetal plasma, in muscular dystrophy, 620-622
hydratase activity of, 155, 163
inhibition properties of, 152-163
kinetic properties of, 61-73, 129-135
in liver of rats
hormonal control of, 287-300
in male rat, 171, 338
in muscle, 22-23, 263, 364, 552. *See also* Muscle CA
p-nitrophenyl phosphatase activity of, 23
phosphatase activity of, 154-156
inactivation by phenylglyoxal, 160-163
unique invariant residues for, 339

- Carbonic anhydrase IV, 341
Carboxyketothylated CA II, at active-site His-64, 115, 123-127
Carboxymethylated CA I, at active-site His-200, 115, 116-122
Carboxypeptidase A, 26
 active center of, 29-30
 catalytic activity of, 37-40
 crystal structure of, 27
Carotid body CA in cat, 398-400
Cartilage CA, 263
Cat CA
 in carotid body, 398-400
 in muscle
 carbon dioxide hydratase activity of, 155
 comparative studies of, 165-176
 kinetics of, 129-135
 in peripheral nervous system, 408-411
Catalase, purification of mRNA from, 324-331
Catalytic activity of CA, 22, 76-77
 active-site modifications affecting, 114-127
 electronic measurements of, 84-88
 and interconversion between CO_2 and bicarbonate, 63-65
 ligand exchange in, 99-103
 "ping-ping-pong" path in, 87, 99, 103-106
 and pK_a of zinc-bound H_2O , 67-69
 proton transfer in, 84-88
 and splitting of O-H bond in H_2O substrate, 65-67
 and transfer of H^+ between active site and reaction medium, 62-63
 zinc role in, 26-47
Cayman CA, 506
Cebus monkey CA
 classification of, 339
 structure of, 183
Cerebellar CA, 361-362, 498
 in audiogenic seizure mice, 502-504
Cerebral CA, 361-362, 498-500
 in audiogenic seizure mice, 502-504
Cerebral calcification, in deficiency of CA II, 268-269
Cerebrospinal fluid
 acetazolamide affecting, 12
 bicarbonate formation in, 574-575
 CA activity affecting, 405, 498, 607-608
Chameleon CA, inhibitors affecting, 506, 522
 and fatty acid synthesis, 525-526
Chicken CA
 in chorioallantoic membrane, 459-470
 vitamin D_3 metabolites affecting, 479-480
erythrocyte, 172, 175, 339
 compared to chorioallantoic membrane CA, 466-467
 epinephrine affecting, 243-244
 inhibition of, 173, 174
 isolation of CA II gene, 332-334
 in muscle, 175, 179-180
 in osteoclasts, 473-477
 in retina, 431-435, 439
 structure of, 183
Chimpanzee CA
 classification of, 339
 structure of, 183
Chloride
 accession to cerebrospinal fluid, 575
 adduct of cobalt CA, magnetic circular dichroic spectra of, 140
 inhibiting CA
 in Australia-9 variant, 259
 in plants, 225, 226
 in red cells, 170, 172, 174, 175, 176
 transport affected by CA, 491
Chloroplast CA, 227, 228, 232
Chlazolamide inhibitor of CA
 comparative studies of, 171
 for kidney membrane CA, 175
Chorioallantoic membrane CA in chicks, 459-470
 antibodies to, 464
 compared to erythrocyte CA, 466-467
 expression during development, 464-465
 immunohistochemistry of, 466
 purification of, 463-464
 role in calcium transport, 467-470
 vitamin D_3 metabolites affecting, 479-480
Choroid plexus CA, 498
 and bicarbonate formation, 574
 in rat, 405-407
Chromatography
 development of, 19
 liquid, of bovine CA, 140-142
Ciliary body, CA inhibitors affecting, 580-581
Ciliary process CA, 364, 377, 610
 and bicarbonate formation, 574
Cimetidine, and oxyntic cell CA activity, 593
Classification of carbonic anhydrases, 339-341
Cobalt CA, 23, 35
 binding of carbon dioxide, 96
 carboxylate resonance in, 116, 119
 compared to other metal-substituted carbonic anhydrases, 96-97
 coordination geometry of ligand adducts, 140
 denaturation and renaturation of, 137-139

- histidines in, 95
 liquid chromatography of, high-performance, 140-142
 proton relaxation at active site in, 101
 second acidic group in, 95-96
 structure of, 89-93
 Colon CA, 263, 394, 615
 cytosolic, 388
 human, 364, 375-376, 387
 in mouse, 387
 in rats, 307
 Comparative studies of carbon dioxide hydration, 165-176
 dimerization in, 168-169
 inhibitors in, 171-172, 176
 methods used in, 166-167
 pH dependence in, 169
 sulfate affecting, 168
 sulfhydryl groups in, 169
 temperature dependence in, 169-171
 Conformational dynamics of CA, 149-151
 Conserved regions of CA, external, 351-353
 Conversion of CA forms, 243
 Coordination geometry of ligand adducts of cobalt CA, 140
 Copper CA, 96, 97
 Copper-zinc superoxide dismutase, crystal structure of, 27, 28
 Coral calcification, and CA activity, 457
 Corneal CA, 377
 side effects from inhibitors of, 615
 Crab CA, 544-546
 Creatine kinase in fetal plasma, in muscular dystrophy, 620-622
 Crustacean CA, 544-546
 Cyanate inhibition of CA
 in CA III, 156-158
 and carboxylate-zinc interaction, 116
 comparative studies of, 172
 in mammalian enzymes, 171
 in nonmammalian enzymes, 173
 2'3' Cyclic nucleotide 3' phosphohydrolase in brain, and activity of CA, 498-500
 Cyclostome red cell CA, 172
 Cysteine residues in nonmammalian CA, 172, 175
 Cystic fibrosis, and activity of CA, 388
 Cytoplasmic CA
 in kidney, 528
 in plants, 227, 229
 Cytosolic CA
 in mouse brain, 504
 and polarity of ion transport in cells, 388-389
 Deficiencies of carbonic anhydrases, 265-271
 in brain, 268-269
 CA I, 338
 CA II, 268-269
 in erythrocytes, 265-267, 270-271, 338
 in eye, 269
 in Japanese, 267, 276
 Dehydration
 of acetaldehyde hydrate, 109-111
 of bicarbonate, 1, 31
 Deuterium isotope effects
 for bicarbonate dehydration, 77
 for carbon dioxide hydration, 65, 77
 Dextran-bound inhibitor of CA, and bicarbonate transport in kidney, 529-531
 Diamox. *See* Acetazolamide
 Diarrhea, from CA inhibitors, 614, 615
 1,4-Diazabicyclo-[2.2.2.] octane, and isotope effects for CA III, 131
 Dichlorophenamide
 clinical uses of, 609
 compared to other CA inhibitors, 615
 in emphysema, 554
 and fatty acid synthesis in liver, 525-526
 side effects of, 614
 Dimerization of muscle CA, 168-169
 Distribution of CA. *See* Localization of CA in tissues
 Diuretic effects of CA inhibitors, 10, 610
 sulfanilamide, 548, 554
 cDNA clones
 for chicken red cell CA II, 332-334
 for rabbit red cell CA I, 324-331
 Dog CA, in kidney, 528
 Dogfish
 lack of CA in lens, 584
 red cell CA inhibition in, 173, 174
 Dosage of CA inhibitors, and physiologic effects, 611-613
 Duodenal CA
 in guinea pig, 401
 inhibitors of, in ulcer therapy, 587-591, 610
 in rats, 307, 401
 Ear function, and CA activity, 12
 Edema, CA inhibitors in, 610
 Eel CA, in retina, 439, 441
 Eggshells
 calcium translocation into chick embryonic circulation, 459-470, 479
 formation of, 576
 and CA activity, 457
 Elasmobranch CA
 in rectal gland, 577, 585
 in retina, 441
- D**arkness, affecting CA inhibitors, 457

- Electrical potential of ciliary body, CA inhibitors affecting, 580-581
- Electron microscopy of CA, 377-380
in choroid plexus of rat, 405-407
in peripheral nervous system, 408
in small intestines of rat and guinea pig, 401
- Embryonic tissue CA, 455
in brain, 481
and calcium transport in chick chorioallantoic membrane, 459-470, 479
in chicken retina, 433-435
membrane-bound, in chick metatarsi, 475
and teratogenicity of inhibitors, 447-455
vitamin D, metabolites affecting, in chick chorioallantoic membrane, 479-480
- Emphysema, acetazolamide in, 554
- Endometrial CA, 8
- Endoplasmic reticulum CA, 408
in brain, 484-489
- Endothelial cell VA, vascular in capillaries. *See* Capillary CA
in oligodendrogliomas, 362
- E-P intermediate of alkaline phosphatase, 36, 45, 46
- Epilepsy. *See* Seizures
- Epinephrine, and CA activity, 243-244, 474-475
- Epithelial cell CA, 382-393
- Equine CA. *See* Horse CA
- Erythrocyte CA, 7, 20, 264, 393, 394
CA I, 549
deficiency of, 338
inactive form in aldosteronism, 302-304
in renal tubular acidosis, 192, 282-283
CA II, 549
deficiency with elevated levels of CA III, 284-285
deficiency with osteopetrosis, renal tubular acidosis and cerebral calcification, 268-269, 282, 285, 310
isolation of gene, 332-334
in chickens, 172, 175, 339
compared to chorioallantoic membrane CA, 466-467
classification of, 339
comparative studies of carbon dioxide hydration, 165-176
compared to salivary enzyme, 214
compared to muscle enzyme, 153, 156
deficiencies of, 265-267, 270-271, 338
in Japanese, 267, 276
epinephrine affecting, 243-244, 474-475
human, 359
measurement of activity of, 415-428
membrane-bound, 475
in menstrual cycles, 280-281
metabolic products of, 188-189
polymorphisms of, 186-188
in pregnancy, 280-281
in rabbits, at 54,000 molecular weight, 241-242
structure of, 183-185
in thyroid disorders, 280
in turtle. *See* Turtle CA, erythrocyte variants in Australasia, 249-260
variations in levels of, 277-278
- Erythroleukemia cells, murine, expression of CA and globin in, 335-337
- Erythropoiesis, expression of CA and globin in, 335-337
- Eskimos, erythrocyte CA in, 277-278
- Esterase activity
of carbonic anhydrases, 190
in CA III, 154-156, 163, 179, 180
in carboxyketoethylated cobalt CA, 125-126
of ubiquitin, 247
- Ethoxzolamide inhibition of CA, 130
and acid secretion, 572
clinical uses of, 609
comparative studies of, 171, 615
and fatty acid synthesis in liver, 525-526
for lens CA, 582-585
measurement of activity in cells, 422-424
for nonmammalian enzymes, 173, 174
in plants, 224
and platelet aggregation, 207-209
properties of, 569
side effects of, 614
teratogenicity of, 448
transcorneal diffusion of, 572
in ulcer therapy, 601-603
and urea production in hepatocytes, 520, 522
- Evolutionary trees for CA, 345-351
- Exercise
and carbon dioxide output of muscle, 552
and carbonic anhydrase activity, 549
- Eye CA, 263
in aqueous humor, 580-581
capillary, 377
corneal, 377
deficiency of, 269
inhibitors of glaucoma, 10, 12, 571-572, 610
in lens, 577, 582-586
plasma levels of inhibitors affecting, 611, 616
retinal. *See* Retinal CA
side effects from inhibitors of, 615
- Face fly larva CA, 219-221
- Fallopian tube CA, 8

Fatty acid synthesis

bicarbonate in, 523

CA role in, 513

and effects of CA inhibitors, 525-526

Fetal lung secretion, CA affecting, 551

Fetal plasma CA III, in muscular dystrophy, 620-622

Fish CA

lack of, in lens, 584

in red cells, 172, 175

inhibition of, 173, 174

in retina, 441, 443

Flounder lens, lack of CA in, 584

Forms of carbonic anhydrase, 20-21

2-Formylamino-1,3,4-thiadiazole-5-sulfonamide, and ciliary body electrical potential, 580-581

Frog red cell CA, 172, 175

inhibition of, 173, 174

Furosemide, and cerebrospinal fluid flow, 607

Gallbladder CA, 364, 377, 615

Gallium, and cerebrospinal fluid formation, 607

Ganglion cell CA, 362, 408

Gastric mucosa CA. *See* Stomach CA

Gastrin, and oxyntic cell CA activity, 592-595

Gastritis, from CA inhibitors, 614

Genes for CA

for CA I, coordinate expression of, 324-331

for CA II, 332-334

human studies of, 317-320

mouse studies of, 312-317

possibility of more than one gene, 269, 318-320

evolution of, 338-356

Gill CA, 544, 553-554

Glaucoma, CA inhibitors in, 10, 12, 571-572, 610

plasma concentrations affecting, 611, 616

Glial cell CA, 366, 394, 481, 494, 498, 504

in avian retina, 432-435

membrane-bound, 481

in mouse retina, 435-438

Globin expression, during erythropoiesis, 335-337

Gluconeogenesis, bicarbonate in, 522

Glucose synthesis from lactate, CA affecting, 511-513

Glutamine synthetase, in neural retina, 432-433

in chicken, 432-433

in mouse, 435-438

Goat CA

in parotid glands, 212-213

in saliva, 214

Goblet cell CA, intestinal, 393

Gorilla CA III, 179

structure of, 183

Granule location of CA in serous cells, 390-393

Guanidine hydrochloride, and denaturation and renaturation of cobalt CA, 137-139

Guinea pig CA

distribution of, 263

in hepatocytes, 521-522

in intestinal goblet cells, 393

in kidney, 383

in small intestine, 401-403

Hagfish red cell CA, 172, 175
inhibition of, 173, 174

Hemoglobin

and evolution of carbon dioxide, 6-7

and expression of CA in erythropoiesis, 335-337

Hexachlorophene intoxication, and CA activity in brain, 494

Histamine, and oxyntic cell CA activity, 592-595

Histidines

active site of, and splitting of H₂O, 67

anion binding of His-200 in CA I, 174

cobalt-bound, 95

modifications of, and catalytic activity, 114-127

Histochemical localization of CA. *See* Localization of CA in tissues

Histochemistry, compared to immunological studies, 366-367, 372-377

Historical studies of CA, 1-24, 547-549

in early years, 4-8

in middle years from 1945 to 1960, 10-16

in years since 1960, 18-24

Horizontal cell CA, in fish retina, 441, 443

Hormones, and activity of CA III in rat liver, 287-300

Horse CA

classification of, 339

polymorphisms of, 186, 187, 188, 190

replacements Gln-67 and Lys-69 in, 345, 359

structure of, 183, 184, 187

Human CA

in brain, 361-362, 364, 366

carboxyketothylated, 123-127

carboxymethylated, 116-122

classification of, 339

- cobalt-substituted, 89-97
comparative studies of carbon dioxide hydration, 165-176
deficiencies of, 265-271
denaturation and renaturation of, 137-139
distribution of, 263-264, 359-367, 394
dynamic NMR studies of, 143-148
electronic mechanism for catalysis of, 84-88
in erythrocytes, 359
genes of. *See* Genes for CA
in kidney, 361, 364, 366, 372-375, 383, 528, 529
kinetic properties of, 61-73
liquid chromatography of, 142
in liver, 364, 387
in peripheral nervous system, 408-411
"ping-pong" view of, 99-106
structure of, 183-186, 187
refinement of, 49-59
Hydratase activity of CA, 190
in CA III, 155, 163, 179
Hydration of carbon dioxide. *See* Carbon dioxide, hydration of
Hydrocephalus, CA inhibitors in, 12, 610
Hydrogen
bonds in CA I, 56
exchange with sodium in glial cells, 491
export in cells with cytosolic CA, 388-389
isotope effects for carbon dioxide hydration by CA III, 129, 131, 134
transfer between active site and reaction medium, 62-63
4 - (2 - Hydroxyethyl) 1 - 1 - piperazineethane sulfonic acid, and isotope effects for CA III, 131
Hyperventilation, and CA activity, 548-549
- I**leal CA
in guinea pig, 401
in rats, 307, 401
Imidazole
as inhibitor of CA I, 21-22
and isotope effects for CA III, 131
Immunohistochemistry
and localization of CA. *See* Localization of CA in tissues
of membrane-bound CA, 196
Immunological studies, compared to histochemistry, 366-367, 372-377
Inhibitors of CA, 69-73, 165, 190. *See also* specific inhibitors
and calcification reactions, 457
in clinical medicine, 10-12, 609-617
choice of, 615-616
optimal dosage in, 616-617
plasma concentrations in, 611-613
side effects of, 613-615
comparative studies of, 171-172
for membrane-bound CA, 197
for muscle CA III, 152-163
for nonmammalian enzymes, 173, 174
pharmacology and chemistry of, 568-572
in plants, 224-226
teratogenicity of, 447-455
Insect CA, in face fly, 219-221
Intestinal CA, 263
aldosterone affecting, 306-308
capillary, 377, 379
in chicken, 174
in colon. *See* Colon CA
duodenal, 307, 401
inhibitors of, in ulcer therapy, 587-591, 610
in goblet cells, 393
ileal, 307, 401
jejunal, 307, 401, 615
in small intestines of rat and guinea pig, 401
Invertebrate CA, and ion transport, 544-546
Iodide transport, thyroidal, CA affecting, 604-606
Iodoacetate, inhibiting CA, 190
Isotope effects
for acetaldehyde hydrate dehydration, 109-111
for bicarbonate dehydration, 77
for carbon dioxide hydration, 65, 67, 77
by CA III, 129, 131, 134
Isozymes of CA, 20-21. *See also* specific carbonic anhydrases
- J**apanese, erythrocyte CA deficiency in, 267, 276
Jejunal CA, 615
in guinea pig, 401
in rats, 307, 401
- K**angaroo CA, erythrocyte, 338
Kidney
acetazolamide affecting, 11, 12, 531-535, 538-539, 541-543
carbonic anhydrase in, 2, 7, 165, 263, 383-387, 394, 548
and ammonia synthesis in alligator, 508-511
and bicarbonate transport, 528-535
capillary, 377, 379, 562-563
cytosolic, 388
deficiency of, 268
electron microscopy of, 377

- in guinea pig, 383
- in humans, 361, 364, 366, 372-375, 383, 528, 529
- membrane-bound, 175, 196, 198, 199, 268, 309, 339, 359, 366, 372-374, 389-390, 528-529
- in mouse, 383
- plasma levels of inhibitors affecting, 612, 616
- and polarity of ion secretion, 389
- in rats, 307, 528, 529
- side effects from inhibitors of, 614
- tubular acidosis of
 - carbonic anhydrase levels in, 192, 268, 282-283
 - inactive CA I in, 303
 - with osteopetrosis and cerebral calcification, 268-269, 282, 285, 310
- Kinetics
 - of carbon dioxide hydration, comparative studies of, 165-176
 - of carbonic anhydrases, 61-73, 76-77
 - in CA III, 129-135
 - in pulmonary capillaries, 565-567
- L**acrimal gland CA, 390
- Lactate, glucose synthesis from, CA affecting, 511-513
- Lamprey CA in retina, 441
- Larval CA
 - in face fly, 219-221
 - in mosquito rectal gland, 576
- Leaf CA. *See* Plant CA
- Lens CA, 577, 582-586
 - side effects from inhibitors of, 615
- Ligands
 - coordination geometry of adducts of cobalt CA, 140
 - water, zinc-bound, 169
- Light, affecting CA inhibitors, 457
- Lipid
 - bilayer membrane pore formation by membrane-bound CA, 201-204
 - synthesis in liver, CA affecting, 525-526
- Liver CA, 165, 263, 615
 - hormonal control of CA III in rats, 287-300
 - human, 364, 387
 - inhibitors affecting fatty acid synthesis, 525-526
 - in male rat, 171, 176, 263, 338
 - inhibition of, 171, 172
 - mitochondrial, 516-523
 - in normal and adrenalectomized rats, 307
- Lizard CA, 506-507
- Localization of CA in tissues, 7, 263-264, 394
 - in carotid body of cat, 398-400
 - in choroid plexus of rat, 405-407
 - in epithelial cells, 382-393
 - and histochemistry compared to immunological studies, 366-367, 372-377
 - in humans, 359-367
 - in mammalian tissue, 369-380
 - in muscle, 412-414
 - in nonepithelial cells, 393-394
 - in peripheral nervous system, 408-411
 - in rats, 307
 - in secretory granules, 390-393
 - in small intestines of rat and guinea pig, 401-403
- Lung CA, 165, 263
 - capillary, 379, 551
 - kinetics and activity of, 565-567
 - and carbon dioxide exchange, 550-551
 - and fetal lung fluid secretion, 551
 - inhibitors affecting chronic obstructive disease, 555, 556, 610
 - localization of, 551
 - membrane-bound, 196, 198, 199, 309, 339, 341, 389, 551-552
 - and plasma pH equilibration, 549-550
- M**anganese CA, 96
 - water molecules in, 112-113
- Magnetic circular dichroic spectra of ligand adducts of cobalt CA, 140
- Measurement of CA activity in cells, 415-428
 - and accessibility factor, 415-416
 - and acetazolamide inhibition, 424-425
 - discrepancies in, 418
 - and ethoxzolamide inhibition, 422-424
 - and methazolamide inhibition, 425-426
 - oxygen-18 exchange technique in, 419-428
- Mechanism of carbonic anhydrase reaction, 31-35
- Membrane-bound CA, 165, 175, 195-204, 264, 309
 - activity of particulate-bound form, 196-197
 - biochemical characteristics of, 196-199
 - in brain, 198, 199, 268, 309, 481, 482
 - in erythrocytes, 475
 - in kidney, 175, 196, 198, 199, 268, 309, 339, 359, 366, 372-374, 389-390, 528-529
 - location of active site, 197
 - in lung, 196, 198, 199, 309, 339, 341, 389, 551-552

- in osteoclasts, 475
- physiological function of, 200-204
- in pituitary, 475
- and pore formation in lipid bilayer membrane, 201-204
- purification of, 197-199
- tissue distribution of, 195-196
- Meniere's disease, CA inhibitors in, 610
- Menstrual cycle, erythrocyte CA in, 280-281
- Mental retardation, in deficiency of CA II, 268-269
- Mesenchymal cell CA, 393
- Metabolic products of carbonic anhydrases, 188-189
- Metabolism affected by CA, 505-515
 - amino acid synthesis, 506-508
 - ammonia synthesis in alligator kidney, 508
 - fatty acid synthesis, 513
 - glucose synthesis from lactate, 511-513
 - in hepatocytes, 516-523
 - urea production in, 518-522
- Methazolamide
 - clinical use of, 609
 - comparative studies of, 172, 615-616
 - in glaucoma, 571
 - and intraocular pressure, 15
 - and lens CA inhibition, 582, 583
 - measurement of activity in cells, 425-426
 - properties of, 569, 571
 - side effects of, 614
 - transcorneal diffusion of, 572
- 2-Methylamino-1,3,4-thiadiazole-5-sulfonamide, and ciliary body electrical potential, 580-581
- 1-Methylimidazole, and isotope effects for CA III, 131
- Microsomes
 - calcium uptake affected by CA activity, 468-469
 - carbonic anhydrase in mouse brain, 504
- Mitochondrial CA, 264, 309, 339
 - hepatic, 516-523
 - in mouse brain, 504
 - in muscle, 552
 - neuronal, 411
 - purification of, 210-211
 - and pyruvate carboxylase inhibition, 522
- Mollusk CA, 457, 544
- Molybdate, inhibiting phosphatase activity of CA III, 156
- Monkey CA
 - cebus, 183, 339
 - rhesus, 183, 187, 339, 408-411
- 4-Morpholine-ethanesulfonic acid, and isotope effects for CA III, 131
- 4-Morpholinepropanesulfonic acid, and isotope effects for CA III, 131
- Mosquito larva rectal gland CA, 576
- Mountain or altitude sickness, CA inhibitors in, 555, 556, 610
- Mouse CA
 - in brain, 494, 495
 - in audiogenic seizure mice, 503-504
 - in quaking mice, 481, 482
 - classification of, 339
 - in colon, 387
 - distribution of, 263, 264, 394
 - expression during erythropoiesis, 335-337
 - genes of CA II, 309-320
 - in kidney, 383, 528, 529
 - in retina, 435-438, 439
 - in spinal cord, 494, 495
 - structure of, 183, 187
 - teratogenicity of inhibitors of, 447-455
 - thyroidal, 604
- Müller glial cells
 - in avian retina, 432-435
 - carbonic anhydrase in, 498, 615
 - in mouse retina, 435-438
- Muscle CA, 22-23, 263, 364, 552. *See also* Carbonic anhydrase III
 - active site of, 179-181, 341-345
 - in capillary endothelium, 263, 552
 - in chicken, 175, 339
 - comparative studies of, 165-176
 - elevated levels with CA II deficiency, 284-285
 - extracellular and extravascular localization of, 412-414
 - in horse, 339
 - inhibition of, 152-163
 - comparative studies of, 176
 - isolation and purification of, 166-167
 - kinetics of, 61-73, 129-135
 - in mitochondria, 553
 - in sarcolemma, 394, 414
- Muscular dystrophy, and fetal plasma CA III, 620-622
- Myelin CA
 - in central nervous system, 393-394, 494-496
 - in mouse brain, 504
 - in peripheral nervous system, 408
 - in rat brain, membrane-bound, 198, 199
 - in sensory nerves, 362
- Neoplastic cell CA, 367
- Neoprontosil
 - complex with CA, 44
 - as inhibitor of CA, 175

- Nervous system CA
 in central nervous system, 393-394, 494-496. *See also* Brain CA
 compartmentalization of CA II in neural retinas, 430-445. *See also* Retinal CA
 in myelin. *See* Myelin CA
 in peripheral nervous system, 366, 408-411
- Neural tube CA, 455
- Neurotransmitter turnover, glutamine synthetase affecting, 432, 433
- Nickel CA, 97
- Nitrate inhibition of CA in plants, 225, 226
- 2-Nitrophenol, inhibiting hydration of CO_2 , 73
- p*-Nitrophenyl acetate, hydrolysis of, 40
- p*-Nitrophenyl acetate esterase
 activity in carboxyketoethylated cobalt enzyme, 125-126
 activity in muscle CA III, 154-156
- 4-Nitrophenyl acetate hydrolase, pH-dependent activity of, 68
- p*-Nitrophenyl phosphatase activity of CA III, 23, 154-156
- Nonmammalian CA, 172-174
 inhibition of, 173, 174
- Nuclear CA, in mouse brain, 504
- Nuclear magnetic resonance studies
 of active-site modifications, 114-127
 cadmium-113 signal in, 41-46
 of cobalt CA, 89-97, 143-144
 of human and bovine CA, 146-148
 phosphorus-31 signal in, 45-46
 of water molecules in manganese CA, 112-113
- O**ligodendrocyte CA, 361-362, 366, 393, 481, 492, 494-496, 498-500, 502
- Optic cup CA, 455
- Orangutan CA
 classification of, 339
 structure of, 183
- Osteoclast CA, 268, 473-477
 membrane-bound, 475
- Ouabain, and cerebrospinal fluid flow, 607
- Oviduct CA
 in birds, 7
 in humans, 8
- Ovine CA. *See* Sheep CA
- Ox CA. *See also* Bovine CA
 classification of, 339
 distribution of, 263
 structure of, 183
- Oxalate adduct of cobalt CA, magnetic circular dichroic spectra of, 140
- Oxovanadium CA, 96
- Oxygen-18 exchange technique, for activity of CA in cells, 419-428
- Oxyntic cell CA, 7, 592-595
- P**ancreatic CA, 263, 362, 364, 366, 377, 387, 394, 615
 and bicarbonate formation, 574
 cytosolic, 388
- Pancreatic secretion, CA inhibition affecting, 12
- Paralysis, periodic, CA inhibitors in, 610
- Parathyroid hormone, and CA activity, 243-244, 268, 269
 in osteoclasts, 474
- Paresthesia, from CA inhibitors, 614
- Parietal cell CA, gastric, 382-383, 388, 394
- Parotid gland CA, 390, 394
 ovine, 212-213, 339
 in rat, 216-218
- Pentacoordinate intermediates, and ligand exchange, 101-103
- pH
 and activity of CA, 100, 477
 of alkaline phosphatase, 36-37
 of carbonic anhydrase, 35-36
 and carboxylate resonance in cobalt CA, 121-122
 of carboxypeptidase A, 37
 and catalytic activity of carboxyketoethylated cobalt CA, 124-125
 and dehydration of acetaldehyde hydrate, 110
 and dehydration of bicarbonate, 76
 and exchange of carbon dioxide and bicarbonate, 63
 high-pH form of CA, 100
 ligand exchange in, 101-103
 and hydration of CO_2 , 76
 comparative studies of, 169, 176
 inhibition of, 80
 by isozyme III, 131-135
 and ionization of zinc-bound H_2O , 67-69
 low-pH form of CA, 101
 and phosphatase or esterase activity of muscle CA III, 154-156
 plasma equilibration affected by lung CA, 549-550
- Phenol, inhibiting hydration of CO_2 , 71, 73
- Phenylglyoxal, and phosphatase activity of CA III, 160-163
- Phosphatase activity of muscle CA III, 154-156
 inactivation by phenylglyoxal, 160-163
 Phosphate inhibition of CA, 171
 for CA III, 156
- Phosphorus-31 nuclear magnetic resonance signal, 45-46

- Phosphoserine intermediates of alkaline phosphatase, 36, 45-46
- Photosynthesis, and CA activity, 229-232
- Phylogenetic survey of retinal CA, 438-441
- Pig CA III, 152-163, 179
- "Ping-ping-pong" mechanism of catalysis, 87, 99, 103-106
- "Ping-pong" mechanism, and kinetics of CO₂ hydration, 62, 65, 71, 95, 106, 109
- Pituitary CA, 199, 263
- membrane-bound, 475
- Placental CA, 8
- Placental transfer of acetazolamide, 450-455
- Plant CA, 222-236
- in algae, 233-234
- catalysis and kinetics of, 227-228
- in chloroplasts, 227, 228, 229, 232
- in cytoplasm, 227, 229
- detection on polyacrylamide gels, 234-235
- distribution and location of, 229
- diversity of, 238-240
- function of, 229-232
- inhibitors of, 224-226
- structure of, 226-227
- in underwater plants, 233
- Plasma levels
- of CA inhibitors, and physiologic effects, 611-613, 616-617
- of fetal CA III, in muscular dystrophy, 620-622
- Platelet CA inhibitors, affecting platelet aggregation, 207-209
- Polymorphisms of carbonic anhydrases, 186-188
- Positron lifetime studies, of CA conformational dynamics, 149-151
- Potassium, glial uptake affected by CA, 491
- Pregnancy
- erythrocyte CA levels in, 280-281
- and fetal lung fluid affected by acetazolamide, 551
- and fetal plasma CA III in muscular dystrophy, 620-622
- and placental CA, 8
- and teratogenic effects of CA inhibitors, 447-455
- Prostate CA, in rats, 307
- Proton transfer in carbonic anhydrase reaction, 31-35, 84-88, 129, 133, 134
- comparative studies of, 174
- facilitation of, 59
- and ligand exchange, 102
- in turnover cycles, 65
- Pyruvate, and amino acid synthesis, 506-507
- Pyruvate carboxylate, inhibition by acetazolamide, 522
- Q**uail CA, in retina, 439
- Quaking mice, brain CA in, 481, 482
- 3-Quinolonecarboxylate adduct of cobalt CA, magnetic circular dichroic spectra of, 140
- 8-Quinolonecarboxylate adduct of cobalt CA, magnetic circular dichroic spectra of, 140
- R**abbit CA
- classification of, 339
- distribution of, 263
- erythrocyte, at 54,000 molecular weight, 241-242
- extracellular extravascular CA in muscle, 412
- in kidney, 529
- in lens, 582-586
- muscle CA III, 152-163, 179
- reticulocyte, isolation of cDNA clones for, 324-331
- structure of, 183, 187
- Rat CA
- in brain, 494, 495, 498
- membrane-bound, 198, 199
- in choroid plexus, 405-407
- distribution of, 263, 264, 307, 394
- hormonal control of CA III in liver, 287-300
- in kidney, 307, 528, 529
- and bicarbonate transport, 531-535, 538-539, 541-543
- in liver of males, 171, 176, 338
- inhibition of, 171, 172
- in muscle, 413-414
- in parotid gland, 216-218
- in peripheral nervous system, 408-411
- in retina, 438, 439
- in saliva, 214-215
- in salivary glands, 387
- in small intestines, 401-403
- aldosterone affecting, 306-308
- in spinal cord, 495
- thyroidal, 604
- Receptors for CA, in brain, 486-489
- Rectal gland CA
- elasmobranch, 577, 585
- in mosquito larva, 576
- in shark, 553
- Reproductive tract CA, 8
- Reptile CA
- in red cells, 172

- in retina, 439
 - role in metabolism, 505-515
 - Respiratory aspects of CA, 547-556
 - Reticulocyte CA, rabbit, isolation of cDNA clones for, 324-331
 - Retinal CA, 498
 - in amphibians, 441
 - in chicken, 431-435, 439
 - in fish, 441, 443
 - human, 364, 366
 - in lamprey eel, 441
 - in mouse, 435-438, 439
 - phylogenetic survey of, 438-441
 - in rat, 438, 439
 - in reptiles, 439
 - side effects from inhibitors of, 615
 - variable compartmentalization of CA II, 430-445
 - Rhesus macaque CA
 - classification of, 339
 - in peripheral nervous system, 408-411
 - structure of, 183, 187
 - mRNA for CA
 - of chicken red cell CA II, 332-334
 - of rabbit red cell CA I, 324-331
 - two populations in brain, 491
 - Rumen epithelium CA, 263
- S**alinity, and CA activity in crustaceans, 544-546
- Saliva CA, 391
 - membrane-bound, 196, 198, 199
 - in rat, 214-215
 - in sheep, 212, 214
 - Salivary gland CA, 263, 390, 393, 394. *See also* Parotid gland CA
 - cytosolic, 388
 - rodent, 387
 - submandibular, 307, 364, 390, 394
 - Sarcolemma CA, 394, 414
 - Satellite cell CA, neuronal, 362, 408
 - Secretory cells
 - CA affecting, 572-576
 - granules in, containing CA, 390-393
 - Seizures
 - and acetazolamide as anticonvulsant, 10, 490-491
 - audiogenic, and brain CA in mice, 502-504
 - CA inhibitors in, 610
 - methazolamide in, 614
 - role of CA in, 490-492
 - Serous cell CA, granule location for, 390-393
 - Sex steroids, and activity of CA III in rat liver, 287-300
 - Shark CA
 - in rectal gland, 553
 - in red cells, 172
 - Sheep CA
 - classification of, 339
 - in parotid glands, 212-213, 339
 - structure of, 183, 187
 - Sheepshead red cell CA, 172, 175
 - inhibition of, 173, 174
 - Shell
 - calcium translocation into chick embryonic circulation, 459-470, 479
 - formation of, 576
 - Shell-less eggs, induced by acetazolamide, 457
 - Side effects of CA inhibitors, 613-615
 - Sleep apnea, CA inhibitors in, 555, 610
 - Snail calcification, and CA activity, 457
 - Sodium
 - accession to cerebrospinal fluid, 575
 - exchange with hydrogen in glial cells, 491
 - Solvent molecules of CA I, localization of, 56
 - Somite CA, 455
 - Spinach CA, 354
 - homologies with human CA I, 355
 - Spinal cord CA, 494, 495
 - Spinal nerve cell CA, 362, 408
 - Steroid hormones, and activity of CA III in rat liver, 287-300
 - Stomach CA, 2, 7, 263
 - carbachol affecting, 475
 - cytosolic, 388
 - human, 364
 - inhibitors in ulcer therapy, 572-573, 587-591, 597-600, 601-603, 610
 - and gastric microcirculation, 601-603
 - in oxyntic cells, 592-595
 - in parietal cells, 382-383, 388, 394
 - in rats, 307
 - side effects from inhibitors of, 614-615
 - Structure of carbonic anhydrases, 21, 183-186, 187
 - after refinement, 53-59
 - and amino acid sequence analysis, 174
 - bovine CA, 187
 - in CA III, 154
 - helical regions in CA I, 56
 - hydrogen bonds in CA I, 56
 - in ovine parotid glands, 212
 - in plants, 226-227
 - pleated sheet region in CA I, 26, 56
 - Submandibular gland CA, 307, 364, 390, 394
 - Subtilisin, structure of, 26, 28
 - 2-Succinylamido-1,3,4-thiadiazole-5-sulfonamide inhibiting CA, and bicarbonate transport in kidney, 529-531

- Sulfanilamide**
and ciliary body electrical potential, 580-581
diuretic action of, 548, 554
as inhibitor of CA, 1, 7, 548
comparative studies of, 171
for nonmammalian enzymes, 173, 174
properties of, 569
Sulfate, and catalytic activity of CA, 68, 100, 168
Sulfhydryls, in muscle CA, 169
Sulfonamides. *See also* Acetazolamide; Neoprontosil; Sulfanilamide
affecting histochemical staining of tissues, 372
as inhibitors of CA, 167, 190
comparative studies of, 171-172, 176
for nonmammalian enzymes, 173, 174
pharmacology and chemistry of, 12, 568-572
Superoxide dismutase, chemical shift of cadmium-113 for, 41, 42
Sweat gland CA, 263, 388
cytosolic, 388
Synaptosomal CA, in mouse brain, 504
- T**
Taste sense, CA inhibitors affecting, 614
Teleost CA
in red cells, 166, 172, 175, 176
in retina, 441
Temperature
and activity of CA, 477
and carbon dioxide hydration, comparative studies of, 169-171
and exchange of carbon dioxide and bicarbonate, 64
and water exchange in manganese CA, 112, 113
Teratogenicity of CA inhibitors, 447-455
Testosterone, and activity of CA, 521-522
in CA III of rat liver, 287-300
Tetrazole, inhibiting hydration of CO_2 , 73
Thermolysin
active center of, 29-30
crystal structure of, 27, 28-29
Threonine, in CA II, 174
Thyroid CA, and iodide transport, 604-606
Thyroid disorders, erythrocyte CA levels in, 280
Timolol, and cerebrospinal fluid flow, 607
Toad CA, in retina, 439
Tortoise CA, in retina, 439
Tracheobronchial cell CA, 364, 390, 394
1,2,4-Triazole, inhibiting hydration of CO_2 , 73
- Trifluoromethazolamide, transcorneal diffusion of, 571, 572
Tryptophan residues, in human and bovine CA, 146
Turtle CA
active-site residues of CA I, 184, 187, 350
erythrocyte, 172, 175, 176, 338-339
inhibition of, 174
structure of CA I, 183
thyroidal, and iodide transport, 604-606
Twins, erythrocyte CA in, 277, 278
- U**
Ubiquitin, 245-247
compared to CA III, 190, 191
hydratase and esterase activities of, 190, 192
Ulcer therapy
acetazolamide in, 572-573, 587-591, 597-600, 610
and gastric microcirculation, 601-603
ethoxzolamide in, 601-603
Ulcisolvanil therapy, in ulcers, 572-573, 587-591
Urea metabolism in hepatocytes, 518-522
- V**
Vitamin D_3 metabolites, and CA activity in chick chorioallantoic membrane, 479-480
- W**
Wallaby CA, 339
Water
and carbonic anhydrase mechanism, 21
exchange of molecules in manganese CA, 112-113
as ligand for zinc, 67-69, 84-85, 101, 169
role in catalytic activity, 84-88
splitting of O-H bond in H_2O substrate, 65-67
structure in active site of CA II, 66
White Americans, erythrocyte CA in, 277-278
- Z**
Zinc
in carbonic anhydrase, 7
acetazolamide binding to, 158
and catalysis mechanism, 26-47
charge density of, and interactions of CA with inhibitors, 82
cobalt substitution for, 89-97
compared to other metals, 35-36, 97
copper substitution for, 96, 97

- interaction with carbon dioxide, 63
 - interaction with carboxylate in carboxymethylated enzyme, 118
 - ligands to, 21-22, 56
 - manganese substitution for, 96, 112-113
 - nickel substitution for, 97
 - oxovanadium substitution for, 96
 - in parotid glands of sheep, 212
 - in plants, 224
 - and structure and kinetics in guanidine hydrochloride, 137
 - ligand configuration at active site, 99-106
 - water ligand bound to, 67-69, 84-85, 101, 169
- Zinc alkaline phosphatase, 36
- compared to cadmium enzyme, 45-46
- Zinc metalloenzymes
- active centers of, 29-30
 - anatomy of, 26-29

